Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.

Specific PHGKB|Cancer|PHGKB

Lung Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Mar 07, 2019

---

• Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.  
  Wang Zhijie et al. JAMA oncology 2019 Feb
• Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns.  
  Peters Matthew et al. Journal of global oncology 2019 Feb 51-7
• Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.  
  Leal Letícia Ferro et al. Scientific reports 2019 Mar 9(1) 3209
• Barriers and Facilitators to the Use of Genomic-Based Targeted Lung Cancer Therapies in the VA: Qualitative Findings.  
  Arney Jennifer et al. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2018 Feb 35(Suppl 1) S53-S57
• Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.  
  Pillappa Raghavendra et al. The American journal of surgical pathology 2018 42(2) 256-263
• Disparities and Trends in Rates of Genetic Testing and Erlotinib Treatment Among Metastatic Non-Small Cell Lung Cancer Patients.  
  Palazzo Lauren L et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019 Feb
• Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America.  
  Pinto Joseph A et al. Ecancermedicalscience 2019 13896
• Implementing TMB measurement in clinical practice: considerations on assay requirements.  
  Büttner Reinhard et al. ESMO open 2019 4(1) e000442
• Prognostic Value of RASSF1A Methylation Status in Non-Small Cell Lung Cancer (NSCLC) Patients: A Meta-Analysis of Prospective Studies.  
  Hu Hao et al. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2019 Feb 1-19
• Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.  
  Blons Hélène et al. Journal of thoracic disease 2019 Jan 11(Suppl 1) S25-S36
• Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.  
  Lantuejoul Sylvie et al. Journal of thoracic disease 2019 Jan 11(Suppl 1) S89-S101
• A two kinase-gene signature model using CDK2 and PAK4 expression predicts poor outcome in non-small cell lung cancers.  
  Wang X et al. Neoplasma 2016 63(2) 322-9
• Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations.  
  Mehrad Mitra et al. Archives of pathology & laboratory medicine 2018 Mar 142(3) 353-357
• Tumor biomarker testing in non-small-cell lung cancer: A decade of change.  
  VanderLaan Paul A et al. Lung cancer (Amsterdam, Netherlands) 2018 11690-95
• Association and clinical implication of the USP10 and MSH2 proteins in non-small cell lung cancer.  
  Zeng Zhi et al. Oncology letters 2019 Jan 17(1) 1128-1138